Agazzi A, Sammassimo S, Laszlo D, Liptrott Sj, Cascio R, Alietti A, Rabascio C, Mancuso P, Pruneri G, Martinelli G
Haematoncology Division, European Institute of Oncology, Via Ripamonti 435, Milan, 20141, Italy.
Ecancermedicalscience. 2009;3:136. doi: 10.3332/ecancer.2009.136. Epub 2009 Jun 4.
VAD, (Vincristine, Doxorubicin and Dexamethasone) was initially proposed as a salvage therapy for myeloma patients in whom prior alkylating agent therapy failed, although in recent years VAD has been surpassed by novel combination therapies with new biological agents such as thalidomide (and its derivative, lenalidomide) and bortezomib. After the excellent results obtained by the novel agents, VAD can no longer be proposed in preparation to autologous transplantation, although there are still indications that VAD remains useful and clinically relevant in the initial treatment of symptomatic multiple myeloma.
VAD方案（长春新碱、阿霉素和地塞米松）最初被提议作为先前烷化剂治疗失败的骨髓瘤患者的挽救疗法，尽管近年来VAD已被沙利度胺（及其衍生物来那度胺）和硼替佐米等新型生物制剂的联合疗法所超越。在新型药物取得优异疗效后，VAD方案不再适用于自体移植的预处理，尽管仍有迹象表明VAD在有症状的多发性骨髓瘤的初始治疗中仍然有用且具有临床相关性。
